Estudo observacional de longo prazo sobre a eficácia e segurança do Lecigon em pacientes com doença de Parkinson avançada (ELEGANCE)
ELEGANCE - Um estudo não intervencional sobre a eficácia e segurança a longo prazo do gel intestinal Levodopa-Entacapone-Carbidopa (Lecigon®) em pacientes com doença de Parkinson avançada em cuidados de rotina
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).
Lecigon® is prescribed by physicians in advanced Parkinson's disease when patients suffer from uncontrollable fluctuations in mobility, so-called motor fluctuations, which cannot be adjusted well with oral treatment, i.e. medication for swallowing.
In this study, data on the effect and possible side effects from everyday treatment with Lecigon® will be collected and scientifically evaluated. The study is intended to supplement the results of previous clinical studies with clinical data in routine medical care, collected from approximately 300 patients.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Study design:
Non-interventional study, primary data collection.
No visits or measurements will be made mandatory by the observational plan. The assignment of patients to Lecigon® not decided in advance by the study's observational plan but falls within current practice. Prescription of Lecigon® occurred before and independently of the decision to include the patient in the study.
The participating centres will offer participation in the ELEGANCE study to all patients who receive treatment with Lecigon® part of routine clinical practice. From patients, who switched to treatment with Lecigon® prior to signing of informed consent, baseline data will be collected retrospectively.
The planned non-interventional study aims to collect real-world data on the effectiveness and safety of Lecigon® as a therapy for advanced Parkinson´s Disease in routine care in Germany and Austria. The study will be expanded to additional European countries as soon as marketing authorisation in these countries and commercial stock will be available.
Primary Objectives:
- Long-term effectiveness of Lecigon®
- Long-term safety of Lecigon®
Secondary Objectives:
- Patient non-motor symptoms and quality of life
- Healthcare resource utilisation by patients
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Contactos e Locais
Locais de estudo
-
-
-
Bad Segeberg, Alemanha, 23795
- Segeberger Kliniken GmbH Neurologisches Zentrum
-
Beelitz-Heilstätten, Alemanha, 14547
- Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
-
Berlin, Alemanha, 10117
- Charité - Universitätsmedizin Berlin
-
Cologne, Alemanha
- Uniklinik Köln
-
Coppenbrügge, Alemanha, 31863
- Krankenhaus Lindenbrunn
-
Essen, Alemanha, 45147
- Klinik für Neurologie - Universitätsklinikum Essen
-
Freiburg im Breisgau, Alemanha, 79106
- Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
-
Göttingen, Alemanha, 37075
- Zentrum für Seltene Erkrankungen Göttingen
-
Marburg, Alemanha, 35043
- Universitätsklinikum Giessen und Marburg
-
Oldenburg, Alemanha, 26122
- Evangelisches Krankenhaus Oldenburg
-
Osnabrück, Alemanha, 49076
- Klinikum Osnabrück GmbH Klinik für Neurologie
-
Tübingen, Alemanha, 72076
- Universitätsklinikum Tübingen
-
Ulm, Alemanha, 89081
- RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH
-
Wolfach, Alemanha, 77709
- Parkinson-Klinik Ortenau
-
-
-
-
-
Sofia, Bulgária, 1113
- Sveti Naum
-
-
-
-
-
Bruges, Bélgica, 8000
- AZ Sint-Jan
-
Edegem, Bélgica, 2650
- Antwerp University Hospital
-
Ghent, Bélgica
- Ghent University Hospital
-
Liège, Bélgica
- University Hospital Liege
-
Tournai, Bélgica, 7500
- Centre Hospitalier de Wallonie picarde (Chwapi)
-
-
-
-
-
Osijek, Croácia, 31000
- UHC Osijek, J. Klinici za neurologiju
-
Rijeka, Croácia
- University Hospital Centre Rijeka (KBC Rijeka)
-
Zagreb, Croácia, 10000
- University Hospital Centre (KBC Zagreb)
-
Zagreb, Croácia, 10000
- Klinička bolnica Dubrava
-
-
-
-
-
Copenhagen, Dinamarca, 2400
- Bispebjerg Hospital
-
-
-
-
-
Ljubljana, Eslovênia, 1000
- Department of Neurology, University Medical Centre
-
Maribor, Eslovênia, 2000
- Univerzitetni klinični center Maribor
-
-
-
-
-
Barcelona, Espanha, 08025
- Hospital de la Santa Creu i Sant Pau
-
Madrid, Espanha, 28040
- Hospital Clínico San Carlos
-
Madrid, Espanha, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, Espanha
- Hospital de la Princesa
-
Seville, Espanha, 41013
- Hospital Virgen del Rocio
-
-
-
-
-
Groningen, Holanda, 97139713
- University Medical Center Groningen
-
-
-
-
-
Budapest, Hungria
- Semmelweis Egyetem Neurológiai Klinika Budapest
-
Pécs, Hungria, 7623
- Pécsi Tudományegyetem Klinikai Központ Szemészeti Klinika
-
Szeged, Hungria, 6725
- SZTE Szent-Györgyi Albert Klinikai Közpon
-
-
-
-
-
Dublin, Irlanda, D07 R2WY
- The Dublin Neurological Institute, Mater Hospital
-
Dublin, Irlanda, D04 T6F4
- St. Vincent's University Hospital
-
-
-
-
-
Brasov, Romênia, 500326
- Emergency Hospital Brasov, Spitalul Clinic Județean de Urgență Brașov
-
Bucharest, Romênia, 050098
- Bucharest University Emergency Hospital
-
Bucharest, Romênia
- Fundeni Clinical Institute
-
Bucharest, Romênia, 011461
- Spitalul Universitar de Urgență Elias
-
Bucharest, Romênia, 020125
- Colentina Hospital Bucharest
-
Cluj-Napoca, Romênia, 400347
- County Emergency Hospital Cluj-Napoca
-
Constanța, Romênia, 900591
- County Clinical Emergency Hospital of Constanta
-
Timișoara, Romênia, 300723
- Timiş County Emergency Clinical Hospital- Neurology 1
-
Timișoara, Romênia, 300723
- Timiş County Emergency Clinical Hospital
-
Târgu Mureş, Romênia, 540136
- Emergency County Hospital Targu Mures
-
-
-
-
-
Gothenburg, Suécia, 413 45
- Sahlgrenska University Hospital
-
Lund, Suécia
- Skånes universitetssjukhus Lund
-
Uppsala, Suécia, 751 85
- Uppsala university hospital
-
-
-
-
-
Brno, Tcheca
- Masaryk university
-
Olomouc, Tcheca
- Fakultní nemocnice Olomouc
-
-
-
-
-
Graz, Áustria, 8036
- Universitätsklinik für Neurologie, Medizinische Universität Graz
-
Hermagor, Áustria, 9620
- Abteilung für Neurologische Rehabilitation, Gailtal-Klinik
-
Innsbruck, Áustria, 6020
- Universitätsklinik für Neurologie, Medizinische Universität Innsbruck
-
Linz, Áustria, 4020
- Kepler Universitätsklinikum
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Treating physician's normal patient pool
Descrição
Inclusion Criteria:
- Adult Patients (18 years old and over) with Advanced Parkinson Disease already under treatment with Lecigon® (for up to 3 months before giving informed consent) in accordance with the Summary of Product Characteristics (SmPC)
- Patients or legal representative must have signed informed consent to participate in the study
- Patients are not taking part in another clinical (interventional) study at the same time
Exclusion Criteria:
- Patients with contraindications as defined in the current version of the SmPC for Lecigon®
- Patients who will not be seen again for their follow up care at the investigator's site after commencement of Lecigon® therapy
- Patients with pump placement or pump use issues, e.g. patients with acute severe illness, patients unable to perform pump therapy, and in case of lacking compliance due to severe dementia, agitation or alcohol abuse
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: OTHER
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in OFF time from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in OFF time (h/day) from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale IV Scores (MDS-UPDRS IV- motor complications) |
24 months
|
|
Change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in motor experiences of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale II Scores (MDS-UPDRS II - motor experiences of daily living) |
24 months
|
|
Change in Daily Levodopa dose from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Daily Levodopa dose [mg/day] from baseline up to 24 months, or treatment or study discontinuation as measured by morning bolus, continuous flow, extra boli, oral doses |
24 months
|
|
Usage of other Anti-Parkinsonian medicinal products from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness of Lecigon® treatment as measured by usage of other anti-Parkinsonian medicinal products (e.g. levodopa, dopamine agonists, Monoamine Oxidase (MAO)-B inhibitors, amantadine from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Usage of the Lecigon® pump from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness of Lecigon® treatment use of programmed pump rate (2 or 3 rates) from baseline up to 24 months, or treatment or study discontinuation will be collected |
24 months
|
|
Change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Clinical Global Impression of Improvement (CGI-I) from baseline up to 24 months, or treatment or study discontinuation as measured by Clinical Global Impression of Improvement Scale Score (CGI-I) |
24 months
|
|
Change in Patient Global Impression of Change from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness of Lecigon® treatment on the change in Patient Global Impression of Change (PGI-C) from baseline up to 24 months, or treatment or study discontinuation as measured by Patient Global Impression of Change Scale Score (PGI-C) |
24 months
|
|
Satisfaction with treatment from baseline up to 24 months or treatment or study discontinuation
Prazo: 24 months
|
To assess the effectiveness with Lecigon®, satisfaction with treatment will be assessed in terms of pump size, weight, noise, handling and overall pump satisfaction from baseline up to 24 months or treatment or study discontinuation as measured by device satisfaction scale score between 0 (absolutely unsatisfied) to 10 (absolutely satisfied) for each item. |
24 months
|
|
Occurrence of AEs and SAEs from baseline up to 24 months or treatment or study discontinuation
Prazo: 24 months
|
To assess the long-term safety of Lecigon® treatment Adverse Events (AEs) and Serious Adverse Events (SAEs) (including drug-related, device- and procedure-related Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs), AEs of special interest) from time of Informed consent to study completion for up to 24 months or treatment or study discontinuation will be collected |
24 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on the change in Non-Motor Symptoms from baseline up to 24 months, or treatment or study discontinuation as measured by Non-Motor Symptom Scale Scores (NMSS) |
24 months
|
|
Change in Sleep Quality from baseline up to 24 months, or treatment or study Discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on the change in sleep quality from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's disease sleep Scale-2 Score (PDSS-2) |
24 months
|
|
Change in Activities of daily living from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on the change in activities of daily living from baseline up to 24 months, or treatment or study discontinuation as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale Ib Score (MDS-UPDRS Ib - non-motor experiences of daily living) |
24 months
|
|
Change in Quality of Life from baseline up to 24 months or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on the change in quality of life from baseline up to 24 months, or treatment or study discontinuation as measured by Parkinson's Disease Questionnaire total score (PDQ-8 or PDQ-39) |
24 months
|
|
Usage of Healthcare resources from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on usage of Healthcare resources as measured by additional hospitalisation due to complications out of scope of nurse support team since the last visit |
24 months
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Body weight from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Body weight (Kg) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in Blood pressure from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Blood pressure (mmHg) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in Pulse from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on vital signs as measured by change in the Pulse (bpm) from baseline up to 24 months, or treatment or study discontinuation |
24 months
|
|
Change in the Liver function tests from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Liver function tests from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the full blood count from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the full blood count including B12 metabolism panel from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the ECG from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the ECG from baseline up to 24 months or treatment or study discontinuation |
24 months
|
|
Change in the Renal function tests from baseline up to 24 months, or treatment or study discontinuation
Prazo: 24 months
|
To assess the impact of Lecigon® treatment on laboratory results as measured by change in the Renal function tests from baseline up to 24 months or treatment or study discontinuation |
24 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- NIS-MA-2020-02
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .